Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.
Pathak R, Hoag J, Goldberg S, Monsalve A, Resio B, Boffa D. Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC. Journal Of Clinical Oncology 2019, 37: 8519-8519. DOI: 10.1200/jco.2019.37.15_suppl.8519.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer Data BaseHigh-risk featuresIIA non-small cell lung cancerAdjuvant chemotherapyStage IBGuideline recommendationsMultivariable Cox proportional hazards regressionBenefit of ACTMulti-agent adjuvant chemotherapyRole of ACSingle-agent adjuvant chemotherapyUse of ACCox proportional hazards regressionStage IB patientsCell lung cancerProportional hazards regressionImmortal time biasNon-academic centersPT2N0 patientsT2a patientsT2b patientsNSCLC patientsSurvival benefitAC patients